Alan Schneyer to Activins
This is a "connection" page, showing publications Alan Schneyer has written about Activins.
Connection Strength
5.111
-
Brown ML, Andrzejewski D, Burnside A, Schneyer AL. Activin Enhances a- to ?-Cell Transdifferentiation as a Source For ?-Cells In Male FSTL3 Knockout Mice. Endocrinology. 2016 Mar; 157(3):1043-54.
Score: 0.496
-
Andrzejewski D, Brown ML, Ungerleider N, Burnside A, Schneyer AL. Activins A and B Regulate Fate-Determining Gene Expression in Islet Cell Lines and Islet Cells From Male Mice. Endocrinology. 2015 Jul; 156(7):2440-50.
Score: 0.474
-
Brown ML, Ungerleider N, Bonomi L, Andrzejewski D, Burnside A, Schneyer A. Effects of activin A on survival, function and gene expression of pancreatic islets from non-diabetic and diabetic human donors. Islets. 2014; 6(5-6):e1017226.
Score: 0.432
-
Ungerleider NA, Bonomi LM, Brown ML, Schneyer AL. Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice. Endocrinology. 2013 Jun; 154(6):2025-33.
Score: 0.409
-
Bonomi L, Brown M, Ungerleider N, Muse M, Matzuk MM, Schneyer A. Activin B regulates islet composition and islet mass but not whole body glucose homeostasis or insulin sensitivity. Am J Physiol Endocrinol Metab. 2012 Sep 01; 303(5):E587-96.
Score: 0.389
-
Brown ML, Kimura F, Bonomi LM, Ungerleider NA, Schneyer AL. Differential synthesis and action of TGF? superfamily ligands in mouse and rat islets. Islets. 2011 Nov-Dec; 3(6):367-75.
Score: 0.371
-
Xia Y, Schneyer AL. The biology of activin: recent advances in structure, regulation and function. J Endocrinol. 2009 Jul; 202(1):1-12.
Score: 0.309
-
Schneyer AL, Sidis Y, Gulati A, Sun JL, Keutmann H, Krasney PA. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology. 2008 Sep; 149(9):4589-95.
Score: 0.293
-
Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology. 2006 Jul; 147(7):3586-97.
Score: 0.253
-
Schneyer A, Schoen A, Quigg A, Sidis Y. Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG). Endocrinology. 2003 May; 144(5):1671-4.
Score: 0.206
-
Welt C, Sidis Y, Keutmann H, Schneyer A. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood). 2002 Oct; 227(9):724-52.
Score: 0.198
-
Sidis Y, Tortoriello DV, Holmes WE, Pan Y, Keutmann HT, Schneyer AL. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin. Endocrinology. 2002 May; 143(5):1613-24.
Score: 0.192
-
Canali S, Core AB, Zumbrennen-Bullough KB, Merkulova M, Wang CY, Schneyer AL, Pietrangelo A, Babitt JL. Activin B Induces Noncanonical SMAD1/5/8 Signaling via BMP Type I Receptors in Hepatocytes: Evidence for a Role in Hepcidin Induction by Inflammation in Male Mice. Endocrinology. 2016 Mar; 157(3):1146-62.
Score: 0.124
-
Dunphy KA, Schneyer AL, Hagen MJ, Jerry DJ. The role of activin in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia. 2011 Jun; 16(2):117-26.
Score: 0.089
-
Stamler R, Keutmann HT, Sidis Y, Kattamuri C, Schneyer A, Thompson TB. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity. J Biol Chem. 2008 Nov 21; 283(47):32831-8.
Score: 0.075
-
Welt CK, Taylor AE, Fox J, Messerlian GM, Adams JM, Schneyer AL. Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis. J Clin Endocrinol Metab. 2005 Oct; 90(10):5582-7.
Score: 0.060
-
Lambert-Messerlian GM, Pinar H, Laprade E, Tantravahi U, Schneyer A, Canick JA. Inhibins and activins in human fetal abnormalities. Mol Cell Endocrinol. 2004 Oct 15; 225(1-2):101-8.
Score: 0.057
-
Sidis Y, Schneyer AL, Keutmann HT. Heparin and activin-binding determinants in follistatin and FSTL3. Endocrinology. 2005 Jan; 146(1):130-6.
Score: 0.057
-
Di Simone N, Schneyer AL, Caliandro D, Castellani R, Caruso A. Regulation of endometrial adenocarcinoma cell proliferation by Activin-A and its modulation by 17beta-estradiol. Mol Cell Endocrinol. 2002 Jun 28; 192(1-2):187-95.
Score: 0.049
-
Tortoriello DV, Sidis Y, Holtzman DA, Holmes WE, Schneyer AL. Human follistatin-related protein: a structural homologue of follistatin with nuclear localization. Endocrinology. 2001 Aug; 142(8):3426-34.
Score: 0.046
-
Schneyer A, Tortoriello D, Sidis Y, Keutmann H, Matsuzaki T, Holmes W. Follistatin-related protein (FSRP): a new member of the follistatin gene family. Mol Cell Endocrinol. 2001 Jun 30; 180(1-2):33-8.
Score: 0.045
-
Schneyer AL, Fujiwara T, Fox J, Welt CK, Adams J, Messerlian GM, Taylor AE. Dynamic changes in the intrafollicular inhibin/activin/follistatin axis during human follicular development: relationship to circulating hormone concentrations. J Clin Endocrinol Metab. 2000 Sep; 85(9):3319-30.
Score: 0.043
-
Fujiwara T, Lambert-Messerlian G, Sidis Y, Leykin L, Isaacson K, Toth T, Schneyer A. Analysis of follicular fluid hormone concentrations and granulosa cell mRNA levels for the inhibin-activin-follistatin system: relation to oocyte and embryo characteristics. Fertil Steril. 2000 Aug; 74(2):348-55.
Score: 0.043
-
Delbaere A, Sidis Y, Schneyer AL. Differential response to exogenous and endogenous activin in a human ovarian teratocarcinoma-derived cell line (PA-1): regulation by cell surface follistatin. Endocrinology. 1999 Jun; 140(6):2463-70.
Score: 0.039
-
Sidis Y, Fujiwara T, Leykin L, Isaacson K, Toth T, Schneyer AL. Characterization of inhibin/activin subunit, activin receptor, and follistatin messenger ribonucleic acid in human and mouse oocytes: evidence for activin's paracrine signaling from granulosa cells to oocytes. Biol Reprod. 1998 Oct; 59(4):807-12.
Score: 0.037
-
Di Simone N, Hall HA, Welt C, Schneyer AL. Activin regulates betaA-subunit and activin receptor messenger ribonucleic acid and cellular proliferation in activin-responsive testicular tumor cells. Endocrinology. 1998 Mar; 139(3):1147-55.
Score: 0.036
-
Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF, Schneyer AL. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab. 1997 Nov; 82(11):3720-7.
Score: 0.035
-
Schneyer AL. Measurement of activin in physiological fluids. Eur J Endocrinol. 1996 Apr; 134(4):401-2.
Score: 0.032
-
Di Simone N, Crowley WF, Wang QF, Sluss PM, Schneyer AL. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology. 1996 Feb; 137(2):486-94.
Score: 0.031
-
Schneyer AL, Hall HA, Lambert-Messerlian G, Wang QF, Sluss P, Crowley WF. Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically. Endocrinology. 1996 Jan; 137(1):240-7.
Score: 0.031
-
Lambert-Messerlian GM, Canick JA, Palomaki GE, Schneyer AL. Second trimester levels of maternal serum inhibin A, total inhibin, alpha inhibin precursor, and activin in Down's syndrome pregnancy. J Med Screen. 1996; 3(2):58-62.
Score: 0.031
-
Schneyer AL, Rzucidlo DA, Sluss PM, Crowley WF. Characterization of unique binding kinetics of follistatin and activin or inhibin in serum. Endocrinology. 1994 Aug; 135(2):667-74.
Score: 0.028
-
Schneyer AL, O'Neil DA, Crowley WF. Activin-binding proteins in human serum and follicular fluid. J Clin Endocrinol Metab. 1992 Jun; 74(6):1320-4.
Score: 0.024
-
Keutmann HT, Schneyer AL, Sidis Y. The role of follistatin domains in follistatin biological action. Mol Endocrinol. 2004 Jan; 18(1):228-40.
Score: 0.013
-
Sidis Y, Schneyer AL, Sluss PM, Johnson LN, Keutmann HT. Follistatin: essential role for the N-terminal domain in activin binding and neutralization. J Biol Chem. 2001 May 25; 276(21):17718-26.
Score: 0.011
-
Wang Q, Keutmann HT, Schneyer AL, Sluss PM. Analysis of human follistatin structure: identification of two discontinuous N-terminal sequences coding for activin A binding and structural consequences of activin binding to native proteins. Endocrinology. 2000 Sep; 141(9):3183-93.
Score: 0.011
-
Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Zhang Z, Ying SY, Schneyer AL, Lauchlan SC, Felix JC. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol. 1998 Apr; 69(1):23-31.
Score: 0.009
-
McConnell DS, Wang Q, Sluss PM, Bolf N, Khoury RH, Schneyer AL, Midgley AR, Reame NE, Crowley WF, Padmanabhan V. A two-site chemiluminescent assay for activin-free follistatin reveals that most follistatin circulating in men and normal cycling women is in an activin-bound state. J Clin Endocrinol Metab. 1998 Mar; 83(3):851-8.
Score: 0.009
-
Wang QF, Tilly KI, Tilly JL, Preffer F, Schneyer AL, Crowley WF, Sluss PM. Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. Endocrinology. 1996 Dec; 137(12):5476-83.
Score: 0.008
-
Besecke LM, Guendner MJ, Schneyer AL, Bauer-Dantoin AC, Jameson JL, Weiss J. Gonadotropin-releasing hormone regulates follicle-stimulating hormone-beta gene expression through an activin/follistatin autocrine or paracrine loop. Endocrinology. 1996 Sep; 137(9):3667-73.
Score: 0.008
-
Wang QF, Khoury RH, Smith PC, McConnell DS, Padmanahban V, Midgley AR, Schneyer AL, Crowley WF, Sluss PM. A two-site monoclonal antibody immunoradiometric assay for human follistatin: secretion by a human ovarian teratocarcinoma-derived cell line (PA-1). J Clin Endocrinol Metab. 1996 Apr; 81(4):1434-41.
Score: 0.008